- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06511154
The Effect of Cognitive Exercise on Upper Extremity Functions, Balance and Cognitive Functions in Multiple Sclerosis
The Effect of Cognitive Exercise in Addition to Physical Exercise on Upper Extremity Functions, Balance and Cognitive Functions in Individuals With Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, progressive, demyelinating disease characterized by myelin sheath damage in the central nervous system that affects more than 2.5 million people worldwide and is more common in young adults aged 20-40 years, especially in women. Like physical impairments, cognitive impairments are a common clinical finding in individuals with MS, both in the early and late stages of the disease. Individuals with MS with cognitive impairment have more difficulty than those without cognitive impairment in participating in social and occupational activities, finding a job, working and performing routine household activities. It is also known that there is a high percentage of individuals with MS with upper extremity involvement in the early stages of the disease. Functional problems in the upper extremities lead to restriction of activity and participation in individuals with MS. Although it is stated that there is a high rate of upper extremity problems in individuals with MS, it is seen that they are not sufficiently understood and analyzed.
When the literature is examined; evidence-based studies examining the effect of cognitive exercise on motor functions in MS in addition to physical exercises are quite limited. In this context, the subject of this study is to examine the effect of cognitive rehabilitation on upper extremity functions, balance and cognitive functions in individuals with MS.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Emine İpek Halatcı, MSc
- Phone Number: 05347708416
- Email: emnepek@gmail.com
Study Locations
-
-
-
Ankara, Turkey, 06010
- Recruiting
- Ankara Yıldırım Beyazıt University
-
Contact:
- Emine İpek Halatcı
- Phone Number: 05347708416
- Email: emnepek@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Being between the ages of 18 and 65
- A definitive diagnosis of MS by a neurologist
- Having an Expanded Disability Status Scale (EDSS) score below 5.5
- No cognitive problems (Mini Mental Test score of 24 and above),
- Graduated from at least primary school
- No change in medical treatment in the last 6 months,
- Not having had an attack in the last 3 months and not using pulse steroid therapy
- Volunteering.
Exclusion Criteria:
- Having hearing and vision problems that prevent communication
- Having a neurological or psychiatric disease other than MS that causes cognitive impairment
- Pregnancy
- Oncological diseases
- Having other vestibular and orthopedic diseases that may affect balance
- Continue with a different exercise therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Treatment group
Patients in this group are the group in which a physiotherapy program consisting of cognitive rehabilitation and core-based upper extremity exercises will be applied.
|
Cognitive rehabilitation is a treatment method used to regain or improve cognitive abilities.For the cognitive rehabilitation program, the Daily Exercise Package of the Norosoft Program, which mainly includes exercises to improve attention, information processing speed, verbal and visual memory functions, will be applied. Core-based Upper Extremity Exercises Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises
Other Names:
Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises
|
|
Active Comparator: Control group
Patients in this group are the group in which a physiotherapy program consisting of core-based upper extremity exercises will be applied.
|
Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive status
Time Frame: Change from baseline at 8 weeks treatment program after.
|
Loewenstein Occupational Therapy Cognitive Assessment (LOTCA) was developed to assess basic cognitive abilities.
It is a standardized method used between 6-70 years of age.
This scale consists of 6 main sections and 26 subtests including orientation, visual perception, spatial perception, motor praxis, visual motor organization and thinking ability.
It takes approximately 30-45 minutes to administer.
|
Change from baseline at 8 weeks treatment program after.
|
|
Upper extremity
Time Frame: Change from baseline at 8 weeks treatment program after.
|
Manual Ability Measure-36: The scale includes 23 items with a wide range of difficulty that measure the functional level of patients. Nine Hole Peg Test: Evaluates unilateral fine motor skills in the upper extremity. It requires the participants to first insert the nine sticks one by one into the nine holes and then remove them as quickly as possible against the clock. Box and Block Test: It is used to measure hand gross skill performance.The patient is asked to transfer the maximum number of blocks, one at a time, from one compartment of a wooden box divided into two compartments to the other within 60 seconds. Jebsen - Taylor Hand Function Test: It is an standardized test used to measure fine and gross motor functions of the hand by simulating daily life activities. It consists of 7 subtests: writing, simulated number spinning, lifting small objects, simulated feeding, stacking, moving large light and heavy objects. |
Change from baseline at 8 weeks treatment program after.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Coordination
Time Frame: Change from baseline at 8 weeks treatment program after.
|
The Finger to Nose Test is a practical test commonly used to assess coordination.
The patient moves his/her arm from the fully extended position to the bent position, touches his/her finger to his/her nose and opens his/her arm again.
The patient performs this movement consecutively.
Another common one is that the patient touches his/her index finger to the clinician's index finger and then touches his/her own nose, this movement is repeated many times while the clinician continuously changes the position of his/her finger.
|
Change from baseline at 8 weeks treatment program after.
|
|
Balance
Time Frame: Change from baseline at 8 weeks treatment program after.
|
Timed Up and Go Test: It is a method that evaluates the person's ability to move and requires both static and dynamic balance. In the test, the person is asked to get up from the chair, walk 3 meters at a safe and normal speed, turn, walk back and sit on the chair and the time is recorded in seconds. A shorter time indicates better balance and mobility. The starting position of the test is standardized. Berg Balance Scale: clinically evaluates functional balance and consists of 14 items related to functional tasks. These activities are ranked from the easiest to the most difficult. The items of the scale include activities requiring both dynamic and static balance. For each item, the level of competence in the activity is indicated by 5 points (0-4), with 0 being "unable" and 4 being "independent and safe". The maximum score is 56 points, with higher scores indicating better balance. |
Change from baseline at 8 weeks treatment program after.
|
|
Fatigue
Time Frame: Change from baseline at 8 weeks treatment program after.
|
Modified Fatigue Impact Scale: Will be used to measure fatigue.
It is a modified version of the Fatigue Impact Scale based on items from interviews with MS patients about how fatigue affects their lives.
It provides information about the effects of fatigue over the past four weeks in the physical (9 items), psychosocial (2 items) and cognitive (10 items) domains.
The scale uses a 5-point Likert scale with 0 being 'Never' and 4 being 'Always'.
An overall Modified Fatigue Impact Scale score of 38 or above is indicative of MS-related fatigue.
|
Change from baseline at 8 weeks treatment program after.
|
|
Position Sense
Time Frame: Change from baseline at 8 weeks treatment program after.
|
Position Sense: Shoulder position sense will be measured for position sense measurement.
Acumar dual digital inclinometer (Acu360, Acumar, Lafayette, USA) will be used to assess shoulder position sense.
Before starting the tests, the test will be taught to the individuals both verbally and with practice in order to minimize the error rate.
Shoulder abduction and flexion will be calculated at 30° and 60ᵒ.
For both movements, the shoulder will start in neutral rotation position.
Individuals will first be made to perform passive movement.
After 3 seconds in this position, the shoulder will be brought to the neutral position.
Afterwards, the individual will be asked to actively move the shoulder to the desired angle and movement and hold this position for 3 seconds with their eyes closed and express it aloud.
Measurements will be repeated in both limbs (non-dominant and dominant) and a rest period of 60 seconds will be allowed between trials.
|
Change from baseline at 8 weeks treatment program after.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disability Status
Time Frame: Change from baseline at 8 weeks treatment program after.
|
The Expanded Disability Status Scale (EDSS) will be used to determine the disability level of the patients.
The scale consists of two parts.
The functional systems section (pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral or other) is graded from "0" no disability to "5" or "6" severe disability.
The second section, assessing ambulation status, is based on the individual's functional system score and walking distance and is graded from "0" normal health to "10" death.
The EDSS score of patients with mild-to-moderate (1-5.5)
disabilities who will participate in the study will be determined by a specialist neurologist.
|
Change from baseline at 8 weeks treatment program after.
|
|
Cognitive Status
Time Frame: Change from baseline at 8 weeks treatment program after.
|
Standardized Mini Mental Test (SMMT): It will be used to identify people who do not have cognitive problems, which is an inclusion criterion in the first stage.
It is a short, easy-to-administer and standardized test that allows cognitive assessment in a short time and is used to determine the cognitive level globally.
The test consists of five sub-headings: orientation, memory, attention, calculation, recall and language and is evaluated on a 30-point scale.
Traditionally, scores between 24 and 30 are considered normal.
|
Change from baseline at 8 weeks treatment program after.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Emine İpek Halatcı, MSc, Ankara Yildirim Beyazıt University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21.03.2024/03-641
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Cognitive Rehabilitation
-
University of North Carolina, Chapel HillUnited States Department of Defense; Foundation of Hope, North CarolinaCompletedTraumatic Brain Injury | Posttraumatic Stress DisorderUnited States
-
Ege UniversityUnknown
-
Vanderbilt UniversityVanderbilt University Medical CenterCompletedBrain Injuries | Dementia | Muscle Disorders | MyopathiesUnited States
-
Istituti Clinici Scientifici Maugeri SpARecruitingCognitive Impairment | Dementia | Vascular Dementia | Dementia, Mixed | Comorbidities and Coexisting ConditionsItaly
-
I.R.C.C.S. Fondazione Santa LuciaCompleted
-
Samsung Medical CenterCompletedMild Cognitive ImpairmentKorea, Republic of
-
Badalona Serveis AssistencialsCompletedCognitive Dysfunction | Aging | Mild Cognitive ImpairmentSpain
-
Sunnybrook Health Sciences CentreFondazione Italiana Sclerosi Multipla; University of Alabama at Birmingham; University... and other collaboratorsCompletedCognitive Impairment | Multiple Sclerosis, Primary ProgressiveCanada
-
Samsung Medical CenterCompleted
-
University Hospital, BordeauxMerck Serono International SA; ARSEP foundationCompletedMultiple Sclerosis | Cognitive RehabilitationFrance